Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

Key facts

Study ID

NCT07251998

Run by

Beijing InnoCare Pharma Tech Co., Ltd.

People needed

172

Starts

2025-12-22

Expected to finish

2027-05-01

Last updated by the study team

2025-12-31

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).
• Male or female subjects aged ≥ 18 years and ≤ 70 years
• A history of plaque psoriasis for ≥6 months at baseline
• Meet the following three criteria:
• Psoriasis Area and Severity Index (PASI) score ≥12
• Static Physician's Global Assessment (sPGA) score ≥3
• Psoriasis affected Body Surface Area (BSA) ≥10%
• The subject requires systemic treatment and/or phototherapy.

You may not qualify if…

• Diagnosed with non-plaque psoriasis.
• Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
• Presence of clinically serious, progressive, or uncontrolled disease.
• Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
• Pregnant or lactating women.
• The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.

Where it is running

• Shanghai Dermatology Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.